| Literature DB >> 31987856 |
Dewi Safitri1, Matthew Harris2, Harriet Potter2, Ho Yan Yeung2, Ian Winfield2, Liliya Kopanitsa3, Fredrik Svensson3, Taufiq Rahman2, Matthew T Harper2, David Bailey3, Graham Ladds4.
Abstract
Supressed levels of intracellular cAMP have been associated with malignancy. Thus, elevating cAMP through activation of adenylyl cyclase (AC) or by inhibition of phosphodiesterase (PDE) may be therapeutically beneficial. Here, we demonstrate that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors with differing selectivity profiles. Forskolin suppressed cell growth in a PKA-dependent manner by inducing a G2/M phase cell cycle arrest. In contrast, trequinsin (a non-selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but also stimulated (independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. Interestingly, a cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a manner analogous to forskolin but not trequinsin. Finally, we demonstrate that concomitant targeting of both AC and PDEs synergistically elevated intracellular cAMP levels thereby potentiating their antiproliferative actions.Entities:
Keywords: Caspase; Cell cycle; Glioma; Phosphodiesterase inhibitors; Proliferation; cAMP
Year: 2020 PMID: 31987856 DOI: 10.1016/j.bcp.2020.113823
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858